About the role
ROLE SUMMARY Since PAXLOVID’s emergency use authorization on 12/22/21, PAXLOVID has helped treat over 25M patients at high-risk from progression to severe COVID-19, which can lead to hospitalization and/or death. PAXLOVID is well-positioned to remain the gold standard in COVID-19 treatment, however the COVID-19 treatment landscape is a rapidly evolving space with significant complexity. Opportunity to increase treatment rates for eligible patients and bolster PAXLOVID’s leadership position in t…